Nischal Sahai
Research Subjects
Nischal Sahai has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Bridget E. Barber
QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
2 shared publications - Jeremy Gower
Department of Infection and Inflammation, QIMR Berghofer, Brisbane 4006, Australia
2 shared publications - Rebecca Webster
Department of Infection and Inflammation, QIMR Berghofer, Brisbane 4006, Australia
2 shared publications Adam J Potter
Infection and Inflammation Program, QIMR Berghofer , Brisbane, Queensland
1 shared publicationAdam J. Potter
Department of Infection and Inflammation, QIMR Berghofer, Brisbane 4006, Australia
1 shared publication- Angelica Fiona Tan
Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia
1 shared publication
Latest Publications
- 10 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (853) , eaec1863
The pyrrolidinamide antimalarial drug MMV367 rapidly clears blood-stage Plasmodium falciparum in healthy adults with experimental malaria
Fast-acting antimalarial drugs are needed to address the emergence of artemisinin resistance in the protozoan parasite Plasmodium falciparum, the major cause of severe malaria worldwide. The pyrrolidinamide antimalarial drug MMV367 (GSK3772701) potentially interferes with parasite metabolism mediated by P. falciparum acyl-CoA synthetases 10 and 11. In this volunteer infection study, the antimalarial activity of MMV367 was tested against blood-stage P. falciparum in 12 healthy malaria-naïve adults. The study participants were inoculated with P. falciparum 3D7–infected erythrocytes on day 0 and received a single oral dose of MMV367 at 3 mg ( n = 3), 5 mg ( n = 2), 10 mg ( n = 1), 20 mg ( n = 3), 90 mg ( n = 2), or 1500 mg ( n = 1) on day 8. All participants received artemether-lumefantrine on or before day 24. Maximum MMV367 plasma concentrations occurred 2 to 4 hours postdose, and the elimination half-life was 12.9 to 18 hours. For doses of ≥20 mg, the parasite clearance half-life was 2.2 to 4.3 hours with viable parasites declining more rapidly (elimination half-life of 1.1 to 2.7 hours). A clearance pharmacokinetic/pharmacodynamic model described the relationship between MMV367 concentrations and parasite killing and subsequent clearance of nonviable parasites. Model-derived efficacy parameters included a minimum inhibitory concentration of 6.3 ng/ml (95% CI, 5.2 to 7.8) and a minimum parasiticidal concentration with 90% of maximum effect of 54 ng/ml (95% CI, 43 to 68). No reduction in in vitro susceptibility to MMV367 or genetic determinants of resistance were observed in drug-exposed parasite lines. Most adverse events were attributed to malaria challenge, and none were serious. Higher MMV367 doses were not associated with an increased incidence or severity of adverse events. These findings support further clinical development of MMV367.
- 10 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (853) , eaec1863
The pyrrolidinamide antimalarial drug MMV367 rapidly clears blood-stage Plasmodium falciparum in healthy adults with experimental malaria
Fast-acting antimalarial drugs are needed to address the emergence of artemisinin resistance in the protozoan parasite Plasmodium falciparum, the major cause of severe malaria worldwide. The pyrrolidinamide antimalarial drug MMV367 (GSK3772701) potentially interferes with parasite metabolism mediated by P. falciparum acyl-CoA synthetases 10 and 11. In this volunteer infection study, the antimalarial activity of MMV367 was tested against blood-stage P. falciparum in 12 healthy malaria-naïve adults. The study participants were inoculated with P. falciparum 3D7–infected erythrocytes on day 0 and received a single oral dose of MMV367 at 3 mg ( n = 3), 5 mg ( n = 2), 10 mg ( n = 1), 20 mg ( n = 3), 90 mg ( n = 2), or 1500 mg ( n = 1) on day 8. All participants received artemether-lumefantrine on or before day 24. Maximum MMV367 plasma concentrations occurred 2 to 4 hours postdose, and the elimination half-life was 12.9 to 18 hours. For doses of ≥20 mg, the parasite clearance half-life was 2.2 to 4.3 hours with viable parasites declining more rapidly (elimination half-life of 1.1 to 2.7 hours). A clearance pharmacokinetic/pharmacodynamic model described the relationship between MMV367 concentrations and parasite killing and subsequent clearance of nonviable parasites. Model-derived efficacy parameters included a minimum inhibitory concentration of 6.3 ng/ml (95% CI, 5.2 to 7.8) and a minimum parasiticidal concentration with 90% of maximum effect of 54 ng/ml (95% CI, 43 to 68). No reduction in in vitro susceptibility to MMV367 or genetic determinants of resistance were observed in drug-exposed parasite lines. Most adverse events were attributed to malaria challenge, and none were serious. Higher MMV367 doses were not associated with an increased incidence or severity of adverse events. These findings support further clinical development of MMV367.
- Open Access
- 22 April 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (3) , e652-e660
Development of an experimental human blood-stage model for studying Plasmodium knowlesi
Background: The zoonotic parasite Plasmodium knowlesi is an increasing cause of human malaria in Southeast Asia. We aimed to develop a P. knowlesi induced blood-stage malaria (IBSM) model to facilitate study of parasite biology, host responses to infection, and activity of antimalarial treatments. Methods: We manufactured and characterised a P. knowlesi parasite bank using the P. knowlesi YH1 strain adapted to grow in human serum. This P. knowlesi bank was evaluated in an IBSM study involving four adults intravenously inoculated with P. knowlesi-infected erythrocytes using a dose escalation strategy (10-fold increases from ∼2,800 parasites). Parasitaemia was monitored by qPCR. All participants received curative treatment with artemether-lumefantrine. Endpoints included safety and infectivity of the P. knowlesi bank. Results: Two of the four participants developed detectable parasitaemia. Participant two (administered ∼28,000 parasites) had detectable parasites (∼6 parasites/mL) immediately prior to protocol-defined treatment on day 21. Participant three (administered ∼280,000 parasites) developed detectable parasites on day 17, peaking at 202 parasites/mL just after protocol-defined treatment on day 24; the parasite multiplication rate over 32 hours (PMR32) was 2.33 (95% CI 1.66-3.25). Participant four (also administered ∼280,000 parasites) did not become infected. Adverse events were mostly mild and unrelated to the challenge agent. Conclusions: A GMP-grade P. knowlesi YH1-HS parasite bank was successfully manufactured and shown to establish patent infection in humans. The finding that only one of two participants became infected at the highest inoculum dose highlights the potential for this IBSM model to evaluate factors influencing inter-individual variability in susceptibility to infection.
- 22 April 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (3) , e652-e660
Open AccessDevelopment of an experimental human blood-stage model for studying Plasmodium knowlesi
Background: The zoonotic parasite Plasmodium knowlesi is an increasing cause of human malaria in Southeast Asia. We aimed to develop a P. knowlesi induced blood-stage malaria (IBSM) model to facilitate study of parasite biology, host responses to infection, and activity of antimalarial treatments. Methods: We manufactured and characterised a P. knowlesi parasite bank using the P. knowlesi YH1 strain adapted to grow in human serum. This P. knowlesi bank was evaluated in an IBSM study involving four adults intravenously inoculated with P. knowlesi-infected erythrocytes using a dose escalation strategy (10-fold increases from ∼2,800 parasites). Parasitaemia was monitored by qPCR. All participants received curative treatment with artemether-lumefantrine. Endpoints included safety and infectivity of the P. knowlesi bank. Results: Two of the four participants developed detectable parasitaemia. Participant two (administered ∼28,000 parasites) had detectable parasites (∼6 parasites/mL) immediately prior to protocol-defined treatment on day 21. Participant three (administered ∼280,000 parasites) developed detectable parasites on day 17, peaking at 202 parasites/mL just after protocol-defined treatment on day 24; the parasite multiplication rate over 32 hours (PMR32) was 2.33 (95% CI 1.66-3.25). Participant four (also administered ∼280,000 parasites) did not become infected. Adverse events were mostly mild and unrelated to the challenge agent. Conclusions: A GMP-grade P. knowlesi YH1-HS parasite bank was successfully manufactured and shown to establish patent infection in humans. The finding that only one of two participants became infected at the highest inoculum dose highlights the potential for this IBSM model to evaluate factors influencing inter-individual variability in susceptibility to infection.